Literature DB >> 1910678

Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease.

P L Cohen1, R A Eisenberg.   

Abstract

The autosomal recessive lpr and gld genes induce in mice multiple autoantibodies and the progressive accumulation of large numbers of non-malignant CD4- CD8- T lymphocytes. The clinical syndromes and immune abnormalities associated with these two nonallelic genes are nearly identical and are also highly dependent on background genes. MRL/lpr mice are particularly severely affected, and they develop a syndrome that is serologically and pathologically similar to human systemic lupus erythematosus (SLE). Abnormal cell marker expression in the aberrant lpr T lymphocytes includes surface antigens normally associated with activated T cells or even with B cells, and it occurs along with enhanced expression of certain oncogenes. The lpr gene results in intrinsic abnormalities of both T and B lymphocytes, yet its location and product are unknown. The gld gene is located on chromosome 1; its product is also unknown. Although many immunological abnormalities are known, the mechanism whereby these two genes induce autoimmunity and lymphoproliferation remains obscure. Further studies of mice bearing these mutant genes are certain to yield insights into systemic autoimmunity and the control of lymphocyte proliferation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1910678     DOI: 10.1146/annurev.iy.09.040191.001331

Source DB:  PubMed          Journal:  Annu Rev Immunol        ISSN: 0732-0582            Impact factor:   28.527


  334 in total

1.  T cell receptor-induced activation and apoptosis in cycling human T cells occur throughout the cell cycle.

Authors:  M Karas; T Z Zaks; J L Liu; D LeRoith
Journal:  Mol Biol Cell       Date:  1999-12       Impact factor: 4.138

2.  Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies.

Authors:  K Nagaraju; N Raben; L Loeffler; T Parker; P J Rochon; E Lee; C Danning; R Wada; C Thompson; G Bahtiyar; J Craft; R Hooft Van Huijsduijnen; P Plotz
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-01       Impact factor: 11.205

3.  TDAG51 is not essential for Fas/CD95 regulation and apoptosis in vivo.

Authors:  J Rho; S Gong; N Kim; Y Choi
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

Review 4.  Maintenance and loss of self-tolerance in B cells.

Authors:  A Iglesias
Journal:  Springer Semin Immunopathol       Date:  2001-12

Review 5.  Isotype-dependent pathogenicity of autoantibodies: analysis in experimental autoimmune hemolytic anemia.

Authors:  S Izui; L Fossati-Jimack; S A da Silveira; T Moll
Journal:  Springer Semin Immunopathol       Date:  2001-12

Review 6.  Regulatory role of CD4+ T cells during the development of contact hypersensitivity responses.

Authors:  A V Gorbachev; R L Fairchild
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

7.  T-cell tolerance: central and peripheral.

Authors:  Yan Xing; Kristin A Hogquist
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-06-01       Impact factor: 10.005

8.  T cell-specific FADD-deficient mice: FADD is required for early T cell development.

Authors:  N H Kabra; C Kang; L C Hsing; J Zhang; A Winoto
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

9.  Widespread susceptibility among inbred mouse strains to the induction of lupus autoantibodies by pristane.

Authors:  M Satoh; H B Richards; V M Shaheen; H Yoshida; M Shaw; J O Naim; P H Wooley; W H Reeves
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

10.  Chronic Inflammation Promotes Skin Carcinogenesis in Cancer-Prone Discoid Lupus Erythematosus.

Authors:  Anniek Zaalberg; Sara Moradi Tuchayi; Amir H Ameri; Kenneth H Ngo; Trevor J Cunningham; Jean-Pierre Eliane; Maia Livneh; Thomas D Horn; Ilana S Rosman; Amy Musiek; Milan J Anadkat; Shadmehr Demehri
Journal:  J Invest Dermatol       Date:  2018-07-17       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.